Storia in 2 fonti

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo3 mesi fa

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

But phase III study testing selinexor plus ruxolitinib splits on its main goals